NASDAQ:TCBP TC Biopharm (TCBP) Stock Price, News & Analysis → AI finds its first serious application (From Wall Street Star) (Ad) Free TCBP Stock Alerts $1.49 -0.04 (-2.61%) (As of 03:59 PM ET) Add Compare Share Share Today's Range$1.49▼$1.6050-Day Range$1.04▼$1.9552-Week Range$0.85▼$26.60Volume64,482 shsAverage Volume3.62 million shsMarket Capitalization$1.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get TC Biopharm alerts: Email Address Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About TC Biopharm Stock (NASDAQ:TCBP)TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.Read More TCBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCBP Stock News HeadlinesApril 6, 2024 | uk.investing.comTC BioPharm eyes expansion with CAR-NK technology LOIApril 4, 2024 | msn.comHyosung invests $1bn in green raw materials for ‘bio-spandex’April 29, 2024 | DTI (Ad)If you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! April 4, 2024 | marketwatch.comTC BioPharm Shares Rise 63% After Letter Intent to Buy Cancer Therapy AssetsApril 4, 2024 | investorplace.comWhy Is TC Biopharm (TCBP) Stock Up 78% Today?April 4, 2024 | markets.businessinsider.comTC BioPharm Enters Non-Binding Letter Of Intent For Acquisition Of NK Platform TechnologiesApril 4, 2024 | finance.yahoo.comTCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform TechnologiesApril 2, 2024 | prnewswire.comTCBP Increasing Treatment Capacity with Expanded Manufacturing ProcessApril 29, 2024 | DTI (Ad)If you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! March 19, 2024 | finance.yahoo.comTCBP Adjourns General Meeting Until a Later DateMarch 18, 2024 | finance.yahoo.comTCBP Announces Exercise of Series D Warrants For CashMarch 6, 2024 | msn.comBeyondSpring, enVVeno Medical, Aptorum Group among healthcare moversMarch 1, 2024 | finance.yahoo.comBryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show"February 27, 2024 | finance.yahoo.com/C O R R E C T I O N -- TC BioPharm/February 27, 2024 | prnewswire.comTCBP Announces Shareholder Update Call on March 5th 2024February 22, 2024 | benzinga.comTC BioPharm (Holdings) Stock (NASDAQ:TCBP), Short Interest ReportFebruary 22, 2024 | msn.comOcugen, Community Health Systems among healthcare moversFebruary 22, 2024 | finance.yahoo.comTCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK TrialFebruary 22, 2024 | prnewswire.comTCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK TrialFebruary 15, 2024 | finance.yahoo.comTC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit EuropeFebruary 15, 2024 | prnewswire.comTC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit EuropeFebruary 14, 2024 | finance.yahoo.comTCBP Provides Shareholder Update and Highlights Upcoming MilestonesFebruary 14, 2024 | prnewswire.comTCBP Provides Shareholder Update and Highlights Upcoming MilestonesFebruary 12, 2024 | seekingalpha.comVUZI, TCBP and MANU among pre-market losersFebruary 9, 2024 | msn.comBioXcel Therapeutics, Synlogic among healthcare moversFebruary 6, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Higher in Tuesday TradingJanuary 29, 2024 | finance.yahoo.comTC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show'See More Headlines Receive TCBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TC Biopharm and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/29/2024Next Earnings (Estimated)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TCBP CUSIPN/A CIK1872812 Webwww.tcbiopharm.com Phone44-14-1433-7557FaxN/AEmployees60Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.56 Current Ratio1.20 Quick Ratio1.20 Sales & Book Value Annual Sales$4.76 million Price / Sales0.22 Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book0.31Miscellaneous Outstanding Shares680,000Free Float677,000Market Cap$1.04 million OptionableNot Optionable Beta0.32 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Bryan L. Kobel (Age 45)CEO & Director Mr. Martin E. Thorp (Age 72)CFO & Director Mr. Christopher CamarraExecutive Vice President of CommunicationsDr. Lauren Bor Ph.D.Head of Commercial Development DivisionKey CompetitorsScinai ImmunotherapeuticsNASDAQ:SCNIAcorda TherapeuticsNASDAQ:ACORSQZ BiotechnologiesNYSE:SQZAcorda TherapeuticsNASDAQ:ACORQGamida CellNASDAQ:GMDAView All CompetitorsInstitutional OwnershipArmistice Capital LLCSold 223,500 shares on 2/13/2024Ownership: 10.882%View All Institutional Transactions TCBP Stock Analysis - Frequently Asked Questions How have TCBP shares performed in 2024? TC Biopharm's stock was trading at $3.17 at the start of the year. Since then, TCBP shares have decreased by 51.7% and is now trading at $1.53. View the best growth stocks for 2024 here. Are investors shorting TC Biopharm? TC Biopharm saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 204,500 shares, a decline of 68.0% from the March 15th total of 638,700 shares. Based on an average daily trading volume, of 4,520,000 shares, the days-to-cover ratio is currently 0.0 days. View TC Biopharm's Short Interest. When is TC Biopharm's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our TCBP earnings forecast. When did TC Biopharm's stock split? TC Biopharm shares reverse split on Friday, December 15th 2023. The 1-20 reverse split was announced on Friday, December 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did TC Biopharm IPO? TC Biopharm (TCBP) raised $17 million in an initial public offering on Friday, February 11th 2022. The company issued 4,100,000 shares at $4.25 per share. EF Hutton served as the underwriter for the IPO. How do I buy shares of TC Biopharm? Shares of TCBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TCBP) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap Profits4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TC Biopharm (Holdings) Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
